TY - JOUR
T1 - Kinetics of Serological Responses in Critically Ill Patients Hospitalized with 2009 Pandemic Influenza A(H1N1) Virus Infection in Canada, 2009-2011
AU - With the CSIS and ROSII Study Groups
AU - Rolfes, Melissa A.
AU - Gross, F. Liaini
AU - Flannery, Brendan
AU - Meyers, Adrienne F.A.
AU - Luo, Ma
AU - Bastien, Nathalie
AU - Fowler, Robert A.
AU - Katz, Jacqueline M.
AU - Levine, Min Z.
AU - Kumar, Anand
AU - Uyeki, Timothy M.
AU - Veguilla, Vic
AU - Division, Influenza
AU - Wood, Gordon
AU - Reynolds, Steve
AU - Dhingra, Vinay
AU - Winston, Brent
AU - Bagshaw, Sean
AU - Kutsogiannis, Jim
AU - Anderson, William
AU - Silverman, Michael
AU - Herridge, Margaret
AU - McGeer, Alison
AU - Aarts, Mary Anne
AU - Marshall, John
AU - Cook, Deborah
AU - McIntyre, Lauralyn
AU - Ahern, Stephane
AU - Khwaja, Kosar
AU - Bandrauk, Natalie
AU - Hall, Richard
AU - Rello, Jordi
N1 - Funding Information:
Financial support. This work was supported by Hoffman-La Roche and the Public Health Agency of Canada.
Publisher Copyright:
© Published by Oxford University Press for the Infectious Diseases Society of America 2018.
PY - 2018/3/13
Y1 - 2018/3/13
N2 - Background The kinetics of the antibody response during severe influenza are not well documented. Methods Critically ill patients infected with 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09), confirmed by reverse-transcription polymerase chain reaction analysis or seroconversion (defined as a ≥4-fold rise in titers), during 2009-2011 in Canada were prospectively studied. Antibody titers in serially collected sera were determined using hemagglutinin inhibition (HAI) and microneutralization assays. Average antibody curves were estimated using linear mixed-effects models and compared by patient outcome, age, and corticosteroid treatment. Results Of 47 patients with A(H1N1)pdm09 virus infection (median age, 47 years), 59% had baseline HAI titers of <40, and 68% had baseline neutralizing titers of <40. Antibody titers rose quickly after symptom onset, and, by day 14, 83% of patients had HAI titers of ≥40, and 80% had neutralizing titers ≥40. Baseline HAI titers were significantly higher in patients who died compared with patients who survived; however, the antibody kinetics were similar by patient outcome and corticosteroid treatment. Geometric mean titers over time in older patients were lower than those in younger patients. Conclusions Critically ill patients with influenza A(H1N1)pdm09 virus infection had strong HAI and neutralizing antibody responses during their illness. Antibody kinetics differed by age but were not associated with patient outcome.
AB - Background The kinetics of the antibody response during severe influenza are not well documented. Methods Critically ill patients infected with 2009 pandemic influenza A(H1N1) virus (A[H1N1]pdm09), confirmed by reverse-transcription polymerase chain reaction analysis or seroconversion (defined as a ≥4-fold rise in titers), during 2009-2011 in Canada were prospectively studied. Antibody titers in serially collected sera were determined using hemagglutinin inhibition (HAI) and microneutralization assays. Average antibody curves were estimated using linear mixed-effects models and compared by patient outcome, age, and corticosteroid treatment. Results Of 47 patients with A(H1N1)pdm09 virus infection (median age, 47 years), 59% had baseline HAI titers of <40, and 68% had baseline neutralizing titers of <40. Antibody titers rose quickly after symptom onset, and, by day 14, 83% of patients had HAI titers of ≥40, and 80% had neutralizing titers ≥40. Baseline HAI titers were significantly higher in patients who died compared with patients who survived; however, the antibody kinetics were similar by patient outcome and corticosteroid treatment. Geometric mean titers over time in older patients were lower than those in younger patients. Conclusions Critically ill patients with influenza A(H1N1)pdm09 virus infection had strong HAI and neutralizing antibody responses during their illness. Antibody kinetics differed by age but were not associated with patient outcome.
UR - http://www.scopus.com/inward/record.url?scp=85044242472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85044242472&partnerID=8YFLogxK
U2 - 10.1093/infdis/jiy013
DO - 10.1093/infdis/jiy013
M3 - Article
C2 - 29342251
AN - SCOPUS:85044242472
SN - 0022-1899
VL - 217
SP - 1078
EP - 1088
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 7
ER -